Hinge Health (NYSE:HNGE) Price Target Lowered to $52.00 at Barclays

Hinge Health (NYSE:HNGE) had its price target lowered by Barclays from $60.00 to $52.00 in a research note published on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Other equities analysts have also issued reports about the stock. Canaccord Genuity Group decreased their price objective on shares of Hinge Health from $65.00 to $53.00 and set a “buy” rating for the company in a report on Wednesday. KeyCorp decreased their price target on Hinge Health from $72.00 to $70.00 and set an “overweight” rating for the company in a research note on Thursday, January 8th. Wells Fargo & Company began coverage on Hinge Health in a report on Thursday, January 8th. They set an “overweight” rating and a $68.00 price target on the stock. Piper Sandler reduced their price objective on Hinge Health from $71.00 to $60.00 and set an “overweight” rating for the company in a report on Friday, January 9th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $59.00 target price on shares of Hinge Health in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Hinge Health currently has an average rating of “Moderate Buy” and an average price target of $57.71.

Hinge Health Stock Performance

Shares of NYSE HNGE opened at $38.60 on Wednesday. The firm’s 50 day moving average price is $43.96 and its 200-day moving average price is $48.86. The company has a market cap of $3.04 billion and a PE ratio of -2.94. Hinge Health has a 52-week low of $30.08 and a 52-week high of $62.18.

Hinge Health announced that its Board of Directors has approved a stock buyback program on Wednesday, November 12th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to reacquire up to 7.2% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity at Hinge Health

In other Hinge Health news, Director Kristina M. Leslie sold 1,250 shares of the stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $45.68, for a total value of $57,100.00. Following the transaction, the director owned 27,750 shares of the company’s stock, valued at approximately $1,267,620. This represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Insight Holdings Group, Llc sold 1,654,440 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $47.76, for a total value of $79,016,054.40. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 2,805,105 shares of company stock valued at $128,216,614 in the last 90 days.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in HNGE. Swiss National Bank grew its position in shares of Hinge Health by 3.5% during the 4th quarter. Swiss National Bank now owns 32,200 shares of the company’s stock valued at $1,496,000 after acquiring an additional 1,100 shares during the period. Nuveen LLC purchased a new position in Hinge Health during the fourth quarter valued at $825,000. LPL Financial LLC grew its holdings in Hinge Health by 46.5% during the fourth quarter. LPL Financial LLC now owns 7,308 shares of the company’s stock valued at $339,000 after purchasing an additional 2,321 shares during the period. Franklin Resources Inc. grew its holdings in Hinge Health by 15.4% during the fourth quarter. Franklin Resources Inc. now owns 635,415 shares of the company’s stock valued at $29,515,000 after purchasing an additional 84,853 shares during the period. Finally, ING Groep NV purchased a new stake in Hinge Health in the fourth quarter worth about $6,549,000.

Hinge Health News Summary

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Q4 results beat across the board — EPS and revenue topped expectations and revenue grew ~45.5% year‑over‑year, driving the rally. Earnings Report
• Positive Sentiment: Hinge raised FY2026 revenue guidance to roughly $732M–$742M (above consensus) and issued Q1 revenue guidance above estimates — a clear reason for investor optimism. Press Release
• Positive Sentiment: Company outlined a ~25% revenue growth target for 2026 and said AI-driven care investments will help scale offerings — supports the medium‑term growth story. AI & Guidance Coverage
• Positive Sentiment: Analysts remain largely constructive: Needham reaffirmed a Buy ($59 PT) and Citizens/JMP kept an Outperform with a $65 target — these notes support further upside from current levels. Analyst Notes Tickerreport
• Neutral Sentiment: Barclays trimmed its price target from $60 to $52 but kept an Overweight rating — mixed signal: still positive stance but a more conservative valuation. Barclays Note
• Neutral Sentiment: Full earnings call transcript is available for detail on margins, win rates, and cash generation — useful for confirming sustainability of trends. Earnings Transcript
• Negative Sentiment: Despite strong results, the stock trades below its 50‑ and 200‑day moving averages and carries a negative trailing P/E; if growth slows or margins disappoint, multiple compression risks exist.

Hinge Health Company Profile

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.